Avadel Pharmaceuticals PLC Sponsored ADR Stock News

Avadel Pharmaceuticals is deeply undervalued, with LUMRYZ and Valiloxybate offering $2B+ peak sales potential in sleep disorders. AVDL's once-at-bedtime Oxybate franchise is clinically superior, patent-protected, and poised to take share from Jazz Pharmaceuticals amid generic threats. Upcoming catalysts include a pivotal litigation outcome with Jazz, rapid patient growth, and pipeline progress,...

A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept.

Avadel's stellar 2024 performance is driven by LUMRYZ's strong revenue growth, positive net income, and robust patient demand. The $20M global licensing deal for valiloxybate diversifies Avadel's pipeline, positioning it for long-term expansion in sleep medicine. Institutional investor interest and a favorable litigation outcome validate Avadel's business model and de-risk its growth trajectory.

DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted a...

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Thomas McHugh - Senior VP, Principal Financial & Accounting Officer and CFO Susan Rodriguez - Chief Operating Officer Gregory Divis - CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laam...

– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceut...

– Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia –

DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET. Morgan Stanley 23rd Annual ...